MMED:CC News and Press, MIND MEDICINE INC. From 09/06/23

Researchers from the Langone Center of Psychedelic Medicine at New York University and the Imperial College London’s Center for Psychedelic Research have published a study suggesting that small doses of MDMA could help reduce the uncomfortable effects of psilocybin and LSD. Psychedelics ...

A recent study published in the “Neuropsychopharmacology” journal has found that 5-MeO-DMT or DMT (5-methoxy-N, N-dimethyltryptamine) may boost structural neural elasticity . The article reported that, after giving mouse models 5-MeO-DMT, researchers found that the psychedelic caus...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team ...

A recent study has uncovered evidence pointing to psychedelic use by Neanderthals thousands of years ago. Strands of human hair found in a Menorca, Spain, burial site gave researchers insight into hallucinogenic use during prehistoric times by some of the earliest species of humans. The hairs c...

A new study published in the journal “ Frontiers in Psychology ” suggests that psychedelic use and mindfulness meditation may trigger leadership improvements and result in positive leadership outcomes. The preliminary study joins a growing body of scientific literature on the ...

– Enhances financial flexibility through multiple clinical catalysts on MM-120 and MM-402 product candidates – - The Company’s ending 2Q2023 cash and cash equivalents of $116.9 million and committed credit facility are expected to fund operations into 2026, if cer...

A recent spending bill report from a major Senate committee has acknowledged that federal prohibition is hindering comprehensive research into psychedelics . Sections within the report encourage federally sponsored studies involving psychedelics and marijuana but note that the two drugs’...

– Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 with enrollment to be concluded in Q3 2023 – – Topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) anticipated in Q4 2023 / Q1 2024 – – MM-402 in ASD on track for Phase 1 clinica...

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it has entered into a license agreement with Ca...

Psychedelics are all the rage these days thanks to a major surge in psychedelic research and media reporting on hallucinogens.  This research has revealed that various psychedelics may have significant mental health benefits, making the substances prime candidates as alternatives for often u...